A Narrative Review of the Factors Impacting Solid Organ Transplant Recipient Participation in Skin Cancer Screening Authors: Will Swansson, Alvin H Chong Published: 2026 ABSTRACT ABSTRACTSolid organ transplant recipients (SOTRs) are at a significantly elevated risk of cutaneous malignancy due to the requirement for lifelong immunosuppressive medications. Regular full skin examinations (FSEs) with a specialist clinician are recommended by most guidelines and are critical for early skin cancer detection. However, screening engagement remains variable. This narrative review synthesises the existing literature examining participation in FSEs amongst SOTRs. Seventeen studies were identified and grouped into patient‐, clinician‐ and system‐level domains. Across studies, adherence varied between countries and healthcare settings. Patient‐level barriers to screening predominantly related to sociodemographic factors. Clinician‐level factors that influenced screening practice included guideline awareness and prioritisation of skin cancer risk. At the system level, structured protocols and access to dermatologists improved screening uptake. Identifying and addressing barriers across these domains may improve screening uptake in this at‐risk population.Keywords: skin cancer, skin cancer screening, solid organ transplant recipients Introduction Solid organ transplant recipients (SOTRs) are patients who have received a donor organ to replace a damaged or failing one. Transplantation significantly improves the life expectancy of patients with end‐stage disease [1]. However, to prevent graft rejection, SOTRs require lifelong immunosuppressive medications, which increases malignancy risk [2, 3]. Non‐melanoma skin cancer (NMSC) is the most common post‐transplant malignancy in countries with a predominantly fair‐skinned population, including Australia [4]. Compared with the general population, SOTRs have a significantly higher morbidity and mortality from NMSC. They have a 65‐ to 250‐fold risk of squamous cell carcinoma (SCC) and a 10‐ to 16‐fold risk of basal cell carcinoma (BCC) [5, 6, 7]. SCCs are more aggressive in this population, with higher rates of lymph node spread, recurrence and mortality [8, 9]. The risk of melanoma ranges from comparable to the normal population to up to ten‐fold higher [10, 11]. In addition to lifelong impaired immunosurveillance, exposure to ultraviolet radiation is the predominant risk factor for NMSC development [12]. Fair skin phenotype, male sex, and age over 60 years confer additional risk [13]. Given these factors, skin cancer prevention and early detection are essential components of post‐transplant care. Alongside photoprotective practices and regular self‐skin assessments, clinician‐led full skin examinations (FSEs) play a central role in reducing morbidity and mortality from cutaneous malignancies. Detecting malignant changes early is critical in SOTRs, as treatment options for advanced disease may be limited by drug–drug interactions and there is a risk of graft rejection with systemic therapies [14, 15]. Australian guidelines and most international guidelines recommend that SOTRs undergo an FSE at least annually with a trained clinician, if not more frequently for high‐risk patients. The type of clinician varies by guideline, ranging from dermatologist, general practitioner (GP), or an otherwise appropriately ‘trained physician’ [16, 17]. The existing literature on SOTRs and skin cancer predominantly focuses on patient knowledge of skin cancer risk and photoprotective practices [18]. More recently, attention has turned to the efficacy and role of chemopreventive agents, such as acitretin and nicotinamide [19]. Whilst important, these represent only part of the prevention and surveillance paradigm. Far fewer studies have examined adherence to clinician‐led FSE protocols and the factors influencing participation. The gap highlights the need for broader synthesis. This narrative review examines adherence to skin cancer screening amongst SOTRs and the factors influencing it. Evidence across the patient, clinician and system levels is reviewed to provide an in‐depth understanding of the current landscape. Aims The primary aim of this narrative review is to investigate global adherence to skin cancer screening in SOTRs, along with the barriers and enablers that influence participation. There are four additional secondary aims: To establish rates of adherence to at least annual clinician‐led FSEs To establish rates of adherence to at least annual clinician‐led FSEs To compare perspectives on skin screening across stakeholder groups, including patients, clinicians and services To compare perspectives on skin screening across stakeholder groups, including patients, clinicians and services To identify any outcomes associated with adherence to clinician‐led FSEs To identify any outcomes associated with adherence to clinician‐led FSEs To identify gaps in the evidence base and highlight areas for future research To identify gaps in the evidence base and highlight areas for future research Methods Search Strategy A comprehensive literature search was conducted on 24 August 2025 to identify studies relevant to patient‐, clinician‐ and system‐level factors influencing the participation of SOTRs in skin cancer screening. The database MEDLINE was used. The key concepts included transplant recipients, skin cancer, screening and related terms. The search strategy utilised controlled vocabulary (MeSH) and free text terms. Boolean operators (AND/OR) were applied to combine key concepts. Papers had to be English language and have full‐text access to be eligible. The search was limited to studies published in the past 20 years to ensure relevance to current clinical practice. Additionally, references from included articles were screened to identify any relevant literature not found in the original search. The full search strategy can be found in Appendix 1. Inclusion and Exclusion Criteria A broad inclusion criterion was adopted to capture research from multiple perspectives. The population included in this review comprised adult SOTRs (≥ 18 years), clinicians involved in transplant care, and transplant centres or services. This approach allowed capture of patient‐, clinician‐ and system‐level data and perspectives on skin cancer screening. Studies that focused on non‐solid organ transplant populations (e.g., bone marrow transplant recipients) or paediatric patients were excluded. Studies were included if they examined factors related to skin cancer screening, such as adherence to screening recommendations, barriers or enablers of participation, or evaluations of interventions to improve screening. Primary research studies of quantitative, qualitative, or mixed methods designs that met the criteria were included. Reviews, opinion pieces, or other publications without original data were excluded. The full inclusion and exclusion criteria can be found in Table 1. TABLE 1Inclusion and exclusion criteria for study selection.InclusionExclusionPopulationStudies involving: –Adult SOTRs a (renal, liver, heart, lung, pancreas, intestinal, or multi‐organ) aged ≥ 18 years, OR–Healthcare providers who deliver or influence skin cancer screening in SOTRs, OR–Transplant centres or healthcare systems relevant to skin cancer screening in SOTRs Non—solid organ transplant patients (e.g., bone marrow transplant recipients) Paediatric transplant recipients (< 18 years) FocusStudies reporting adherence, barriers, enablers, or interventions related to skin cancer screening participationStudy Design Quantitative studies (surveys, cohort, intervention), OR Qualitative studies, OR Mixed methods studies Publications without original dataOther Published within the last 20 years (2005–2025) English language a SOTR, Solid Organ Transplant Recipient. Inclusion and exclusion criteria for study selection. –Adult SOTRs a (renal, liver, heart, lung, pancreas, intestinal, or multi‐organ) aged ≥ 18 years, OR Adult SOTRs a (renal, liver, heart, lung, pancreas, intestinal, or multi‐organ) aged ≥ 18 years, OR –Healthcare providers who deliver or influence skin cancer screening in SOTRs, OR Healthcare providers who deliver or influence skin cancer screening in SOTRs, OR –Transplant centres or healthcare systems relevant to skin cancer screening in SOTRs Transplant centres or healthcare systems relevant to skin cancer screening in SOTRs Non—solid organ transplant patients (e.g., bone marrow transplant recipients) Paediatric transplant recipients (< 18 years) Quantitative studies (surveys, cohort, intervention), OR Qualitative studies, OR Mixed methods studies Published within the last 20 years (2005–2025) English language SOTR, Solid Organ Transplant Recipient. Results The process of study identification is shown in Figure 1. The MEDLINE search yielded 1925 articles, which were screened by title and abstract. 93 studies underwent full‐text review. A total of 17 studies met the criteria and have been included. Common reasons for exclusion were a focus entirely on photoprotection or general risk awareness without relevant data on skin examinations by specialist clinicians (n = 34), no outcomes of interest (n = 22) and irrelevant topics (n = 8). Flow diagram for the identification and selection of studies. Study Characteristics and Overall Quality The included studies varied in design and scope. Most were cross‐sectional surveys of either patients, clinicians, or transplant centres. There was also a smaller number of interventional, qualitative, and retrospective cohort studies. The studies spanned multiple countries, with Australia contributing the greatest number (n = 5). Although the inclusion criteria spanned 20 years, almost all relevant studies were published within the past 10 years, highlighting that the overall evidence base is relatively recent. Kidney transplant recipients were the most frequently studied group. Many studies, however, contained a mixed SOTR cohort. Sample sizes ranged from 25 in the smaller interventional studies through to over 10,000 in the largest retrospective cohort study. Studies were grouped into three broad groups for synthesis: Patient‐focused studies (n = 11) Patient‐focused studies (n = 11) Clinician‐focused studies (n = 3) Clinician‐focused studies (n = 3) System‐focused studies (n = 3) System‐focused studies (n = 3) Patient‐Focused Studies A total of 11 studies included in this review examined patient‐level behaviours and experiences related to skin cancer screening [20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30]. The key characteristics of the studies are shown in Appendix 2. The studies varied in design, aims and outcomes. Most were cross‐sectional surveys, although several had an interventional component. Definitions of ‘screening’ were inconsistent, ranging from dermatologist‐led FSE to GP‐surveillance to self‐skin examinations. Adherence rates ranged across settings and study designs. In one large Canadian population‐based cohort study, only 2.1% of SOTRs were adherent to annual assessment over the follow‐up period [22]. By contrast, Australian studies overall reported moderate to high adherence, ranging from 43.9%–90% [23, 25, 26, 30]. Different approaches were used to identify barriers to skin cancer screening. Some applied statistical analysis and identified sociodemographic predictors of uptake. Predictors included non‐white race, lower income, non‐English speaking and younger transplant patients [22, 26, 29]. One study highlighted a screening rate of just 7.7% in non‐English speaking patients, compared to 45.1% in English speaking patients. This was possibly even underreported due to the low response rate from their non‐English speaking cohort [26]. Other studies directly captured patient experience. For example, one multi‐country survey highlighted patient‐reported obstacles such as wait times, stress, and overall burden associated with FSEs [20]. Several studies identified factors that promoted screening participation. These included demographic characteristics such as higher income and educational level, and health‐related factors such as a history of skin cancer, prior dermatology visits, and single‐organ rather than multi‐organ transplantation [21, 22]. Educational interventions were also effective, with two small cohort studies demonstrating improved short‐term adherence following a multimodal education program [27, 30]. Some studies examined outcomes associated with screening adherence. One study found that annual FSE was associated with a significantly lower incidence of advanced keratinocyte carcinoma [22]. Another study demonstrated that patients who had seen a dermatologist had better compliance with sun protective measures such as regular sunscreen use [24]. This highlights a potential dual benefit of clinician‐led regular FSEs, which offer an opportunity to provide education and reinforce preventative behaviours in addition to early detection of malignant changes. Clinician‐Focused Studies A total of three clinician‐focused studies were included for review [31, 32, 33]. Key findings are summarised in Appendix 3. All three were cross‐sectional surveys exploring clinician practices and perceptions of skin cancer screening in SOTRs. Clinician‐reported screening practices were variable across the different settings. In one Canadian study, just over half of all transplant clinicians (53%) ensured their high‐risk patients adhered to annual screening [31]. In this study, high‐risk was defined as white race. This was despite clinicians rating the importance of FSE highly (median of 10/10 on a Likert scale assessment). The presence of a formal screening policy and a dermatologist within a transplant unit were enablers of adherence, associated with significantly higher rates of annual screening [31]. One study found that just 19% of the surveyed US physicians had skin cancer screening as part of their post‐transplant protocol [32]. Across the three studies, several barriers to screening were identified at multiple levels. Reported service‐related barriers included long wait times, lack of availability of specialists, and distance from dermatology services [31, 32]. Clinician‐perceived patient barriers were also reported, including financial constraints, limited awareness of skin cancer risk, and insufficient prioritisation of skin assessment in the setting of competing health issues [31, 33]. Finally, clinician‐related barriers were identified. One study reported that 84% of physician respondents were unaware of the American Academy of Dermatology (AAD) skin cancer screening recommendations for transplant patients [32]. Many also perceived that skin cancer screening was not an important part of transplant aftercare, or that there was insufficient evidence to justify universal screening in this population. These perceptions were tied to reduced referrals to dermatology and inconsistent integration of skin cancer screening in post‐transplant protocols [32]. These findings illustrate how clinician perceptions, guideline awareness, and service capacity influence SOTR screening uptake, with downstream effects on patient participation. System‐Level Studies Three studies examined skin cancer screening practices at the service or institutional level [34, 35, 36]. The key characteristics are summarised in Appendix 4. Two were cross‐sectional survey studies of transplant centres, where the centre practices were reported by either the transplant coordinator or another designated institution representative [34, 35]. The other was a single‐centre observational study investigating adherence pre‐ and post‐implementation of institutional changes [36]. The definitions of skin cancer screening varied. Two studies explicitly distinguished between surveillance, defined as inspection limited to exposed skin and patient‐reported lesions, and FSE specifically, and reported adherence rates separately for each of these [34, 35]. In a UK national survey, only 31% of transplant centres performed annual FSE amongst their cohort, and those that did mostly used non‐dermatologists [34]. These findings were similar to an earlier UK study with only 39% of centres performing FSE, again mostly by non‐dermatologists. In comparative analysis, Australian centres generally had more structured protocols and consequently had a higher proportion of centres offering FSEs, most of which were performed by dermatologists [35]. One study described the experience at a peripheral Italian centre, where liver transplant patients demonstrated low adherence. Implementation of structured follow‐up schedules, as well as patient education, improved adherence even in a resource‐limited setting [36]. Discussion This review examined adherence to skin cancer screening in SOTRs and the factors influencing participation. 17 studies were included, spanning multiple countries and research designs. To capture a comprehensive picture of the challenges and supports surrounding screening, studies were synthesised from across three levels of the screening paradigm: patient‐focused, clinician‐focused and service‐focused studies. Across the body of literature, there was substantial variability in screening practice and adherence to guideline recommendations, as well as various identified factors that influence participation. Protocol Variability and Guideline Inconsistencies Although most guidelines encourage at least annual skin cancer screening, these are based on consensus amongst field experts rather than high‐level evidence [37]. Some protocols advise commencing screening after a first skin cancer diagnosis [38], or alternatively stratifying patients into risk groups to guide initiation and frequency of checks [39]. Furthermore, there are also inconsistencies on a protocol level on when to initiate screening. Some recommend initiating pre‐transplant, whereas others do not mention initiation [16, 17, 40]. This correlates with the overall low rates of pre‐transplant screening initiation seen in the included studies [31, 32]. Notably, one separate Australian study reported that 27% of transplant deaths in one cohort within the first four years post‐transplantation were attributable to an untreated skin cancer [41], highlighting the possible morbidity and mortality benefit in establishing patients in screening early. Early referral to dermatologists also allows for education and discussion around prophylactic therapies, depending on the patient's risk profile. Another source of inconsistency is the distinction between skin ‘surveillance’ and FSE. Surveillance may only involve assessment of exposed areas or patient‐reported lesions. In SOTRs, this is usually inadequate, as up to one‐third of NMSC in this group arises in areas typically covered, such as the trunk and legs, which therefore may be missed with just a ‘surveillance’ model [42]. However, it is important to acknowledge that some patients may feel uncomfortable with an FSE due to cultural, religious, or other beliefs. Future research could investigate patient perspectives regarding this to help tailor screening programs that are culturally inclusive, respectful, and responsive to patient needs. Patient and Clinician Determinants of Participation The care of transplant patients is inherently complex, and skin cancer screening only represents one component. Transplant patients face lifelong monitoring of organ function, immunosuppression, surveillance for infections and other cancers, as well as other comorbidities, which require frequent clinic visits [43, 44]. Patients may experience screening as burdensome or deprioritised in this setting of competing health priorities [20]. Likewise, although clinicians broadly recognise the elevated skin cancer risk, some perceive it to be of lower priority compared with other competing health issues [31, 32]. During consultations, transplant clinicians are often faced with more immediately pressing issues, such as maintaining graft function; risks such as cancer may not seem imminent in isolated reviews [45]. Beyond competing priorities, participation is shaped by demographic and social determinants. Non‐white race, lower income, and lower English proficiency were identified as barriers to screening [21, 22, 26, 29]. However, guideline heterogeneity can complicate interpretation, given that some recommend stratifying timing and frequency by subgroup. For example, the first American multidisciplinary expert consensus on skin cancer recommended that high‐risk Caucasian SOTRs undergo an FSE with a dermatologist within 2 years after transplant. High risk in this context is defined as undergoing a thoracic organ transplantation (heart or lung), aged 50 years or over, or male sex. In contrast, the consensus advised that the first FSE could be delayed up to 5 years post‐transplantation for low‐risk Caucasians, Asians, Hispanic and high‐risk African American patients [40]. This reflects how demographic‐based stratification may influence clinical recommendations, in turn contributing to variability in practice and patient uptake, rather than these factors being a true barrier. In resource‐stretched settings, centres may be inclined to adopt a risk stratification model instead of blanket annual screening. However, even with a risk stratification model, some experts contend that all SOTRs should undergo annual screening at a minimum, with high‐risk groups screened every 3–6 monthly [16]. Although non‐Caucasian transplant recipients are at an overall reduced risk of skin cancer, they are particularly prone to development in sun‐protected areas [46]. Moreover, such skin cancers have higher morbidity and mortality [47]. Low perceived risk and limited knowledge contribute to often delayed diagnoses and worse outcomes from skin cancer in people of colour more broadly [48, 49]. These findings highlight the need for equitable, consistent approaches that do not overlook vulnerable groups despite perceived risk differences. Benefits of Regular Screening Only one study in this review reported morbidity outcomes from screening adherence [22]. Future prospective cohort studies, conducted across different healthcare settings, could further investigate the impact of screening on long‐term morbidity. Another study suggested that patients who were more compliant with strict multifaceted photoprotective practices were more likely to comply with annual skin assessment [23]. Similarly, multiple studies outside the inclusion criteria reported an association between regular dermatological assessment and better multifaceted photoprotective practices, for example, regular sunscreen use and utilising covering clothing [50, 51]. Although potentially confounded, it reveals a possibility that regular clinician‐led FSE provides an important educational effect. FSEs offer an opportunity not just for early detection of malignancy, but also for discussions around risk awareness and tailored advice. Importantly, the same factors associated with poor adherence to screening (e.g., male sex, education level, young age) have also been associated with overall poorer photoprotective measures and overall poorer skin cancer risk perception [28, 48]. Future research could explore targeted educational intervention in these at‐risk subgroups, aiming to enhance awareness, photoprotective measures and FSE adherence. System‐Level and Service Delivery Factors Transplant centres play a pivotal role in shaping skin cancer surveillance in SOTRs. Transplant centres are centralised hubs for coordinating most aspects of pre‐, peri‐ and post‐transplant care. They are responsible for initiating and structuring institutional protocols related to transplant care, including skin cancer screening. The presence of a formal screening policy, access to dermatologists within the centre, and availability of trained staff played a pivotal role in determining downstream engagement in skin cancer screening [34, 35, 36]. Integrating dermatologists into the multidisciplinary team also enables more direct communication with transplant physicians, particularly important in cases where alterations need to be made to an immunosuppressive regimen due to NMSC burden [52]. In fact, in the UK, the National Institute for Clinical Excellence (NICE) guidelines have previously suggested a dedicated transplant skin clinic within centres [53]. Australia could be a model for this, as many transplant centres already incorporate dermatology involvement or streamlined referrals [35]. Future research could explore the cost–benefit of embedding dermatology into transplant centres, assessing improved adherence and early detection against the resource expenditures. This is particularly important in the broader global context, where access to dermatologists is often constrained by long wait times, even in high‐income countries [54, 55, 56]. If access to dermatologists remains limited, a shared‐care model involving trained general practitioners (GPs) performing FSEs represents the main alternative approach. However, even with this model, transplant centres should maintain responsibility for initiating screening protocols and identifying high‐risk patients, as they remain central to coordinating longitudinal care. If referring to GPs for FSEs, transplant centres should ideally direct patients to practitioners with extra training or a special interest in skin cancer medicine [57]. Another potential model in resource‐limited settings could be for transplant physicians with additional training to perform basic examinations during routine visits, with referral to dermatologists for complex cases or lesions of concern. This approach has not been formally evaluated in the published literature. Although this may reduce appointment burden and improve accessibility, its feasibility may be limited by competing clinical priorities and time constraints during routine consultations. Limitations This review has several limitations. Included studies were heterogeneous in design, methodology and outcome definitions. This limits formal quantitative synthesis and restricts the review to a narrative approach. Most of the included studies were self‐reported cross‐sectional survey studies, which introduces recall bias. The largest study, which utilised registry‐linked data rather than self‐report, demonstrated significantly lower adherence to screening compared with the others, suggesting self‐reported data may overestimate participation [22]. Further research using registry‐based or otherwise objective data could help validate adherence rates and predictors. To our knowledge, there has been no such recent study in an Australian setting. Another limitation of cross‐sectional surveys is selection bias. For example, English‐speaking patients were much more likely to respond to their survey than non‐English‐speaking patients [26]. On a broad scale, this can lead to under‐representation of minority and marginalised groups. Future studies could deliberately focus on such groups, utilising translated surveys, interpreters, and culturally adapted methodologies to better capture participation data and ensure equity in findings. Unmeasured confounding factors also limit conclusions from the studies. For example, the finding that lung transplant patients demonstrated comparatively lower adherence to screening may reflect underlying socio‐demographic factors rather than the transplant type itself [22]. Finally, an assumption underlying many of the included studies is that follow‐up with a dermatologist equates to a full skin examination. Dermatologist appointments, even with SOTRs, can range in scope, and therefore, this assumption may overestimate adherence and derived predictors in several instances. Conclusion SOTR adherence to skin cancer screening and factors influencing participation were examined in this narrative review. Across the 17 included studies, there was variation in screening practice. Factors were identified at the patient, clinician, and system levels. At the patient level, sociodemographic factors such as lower income, limited English proficiency and non‐white race were associated with reduced screening participation [21, 22, 26, 29]. These reflect broader health inequities that extend beyond just care of SOTRs and skin cancer screening, aligning with the well‐established social determinants of health which shape access to healthcare, preventative behaviours, and outcomes across the spectrum of disease [58]. At the clinician‐level, screening practices were influenced by clinician awareness, competing priorities, and perceived patient barriers [31, 32, 33]. At the system‐level, the presence of structured protocols, dermatology involvement, and referral pathways within transplant centres enabled better access [34, 35, 36]. Practical strategies to improve SOTR participation in FSEs should therefore address factors across these levels. SOTR care should recognise the social determinants that may limit participation in screening and incorporate appropriate strategies to reduce their impact. Clinicians involved in transplant care should be familiar with the current skin cancer screening guidelines for SOTRs and remind patients to undergo regular screening. Finally, transplant centres should also implement structured protocols and referral pathways and integrate dermatologists where possible. Improving FSE participation can help reduce morbidity and mortality from skin cancer in this vulnerable population. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements AI Declaration: AI was used in preparation of this manuscript. In the final stages of revision, the manuscript was inputted into ChatGPT to correct any minor grammatical or sentence structure errors. Small changes were made based on the output. MEDLINE (Ovid) Search Strategy Characteristics and Key Findings of Included Patient‐Focused Studies Author, yearCountryTransplant typeStudy designOverall study aimNumber of participantsAdherence to screening dataFurther data relevant to review aims (barriers, enablers, adherence outcomes, other)Basset Seguin, 2019Europe (multi‐country: France, Italy, Spain and Germany)MixedCross‐sectional surveyExplore patient behaviours, monitoring practices, and perceived barriers to skin cancer screening.200 75% monitored by dermatologist, 23% by dermatologist and GP. Frequency: 36% saw dermatologist every 3 months vs. 71% saw GP every 3 months. Barriers to screening (patient‐reported): follow‐up perceived as burdensome, associated stress and wait times.Borghi, 2016ItalyRenalCross‐sectional surveyAssess awareness of skin cancer risk (including need for regular screening).132Nil Awareness: 49% recognised the importance of regular full skin checks. Enablers of screening awareness (statistical predictors): Young age, higher educational level and previous dermatological visits. Chan, 2019CanadaMixedRetrospective cohortEvaluate association between adherence to annual assessment and keratinocyte carcinoma morbidity and mortality:10,1832.1% adherent to annual assessment with dermatologist in follow up period. Barriers to screening (statistical predictors): non‐Caucasian, male sex and lung transplant. Enablers of screening (statistical predictors): History of precancerous or cancerous skin lesion, single organ transplant (vs. multiorgan), urban residence, high income, care through high adhering centre, and more recent transplant years. Outcomes: Adherence associate with reduced keratinocyte carcinoma related morbidity/mortality. Hartman, 2018AustraliaKidney and LiverRetrospective cohortDetermine whether participation in a skin cancer research study, without any targeted intervention, would lead to an increase in photoprotective behaviours.22552.7% adherent to annual assessment with dermatologist.NilKırnap, 2018TurkeyMixedCross‐sectional surveyEvaluate skin cancer awareness and photoprotective practices7014.3% adherent to annual assessment with dermatologist.Outcomes: Examination with a dermatologist (at least once) resulted in increased sunscreen use.Leung, 2018AustraliaKidneyCross‐sectional telephone interviewCompare renal transplant recipients photoprotective behaviours with the general population.17969% screened in the past 12 months (provider: 86% dermatologist, 23% transplant physician/nurse, 19% GP).NilLow, 2021AustraliaLiverCross‐sectional surveyEvaluate insight into transplant associated risk and participation in preventative practices.21942.9% adherent to annual assessment (provider not stated).Barriers to screening (statistical predictors): Non‐Caucasian, non‐English speaking, younger patients.Sorensen, 2017USAHeartSingle‐arm educational intervention studyDevelop and integrate multimodal skin cancer education program to increase knowledge and protective behaviours.2564% screened in 12 months pre‐intervention. 100% had follow‐up arranged post intervention.Enablers of screening: Structured multimodal educational program.Traboulsi, 2019CanadaMixedCross‐sectional surveyCharacterise photoprotective practices and identify predictors of poor adherence and barriers to such practices.30036% adherent to annual assessment. Provider defined as ‘specialist involved in patient's transplant care’NilWang, 2022USAMixedCross‐sectional surveyAssess and compare skin cancer attitude, behaviour, and knowledge between skin of colour and non‐skin of colour transplant recipients.21944% adherent to at least annual assessment with dermatologist.Barriers (statistically derived): Non‐white race (comparatively statistically significant proportion had never seen a dermatologist)Zaw, 2022AustraliaKidneySingle‐arm educational intervention studyAssess photoprotective practices, skin cancer knowledge, and engagement with screening pre and post educational intervention.25High baseline GP full‐skin check rate (80%) → 92% at 3 months post educational intervention→ 96% at 6 months post intervention (not statistically significant)Enablers of screening: Structured multimodal educational program (although not statistically significant). 75% monitored by dermatologist, 23% by dermatologist and GP. Frequency: 36% saw dermatologist every 3 months vs. 71% saw GP every 3 months. Awareness: 49% recognised the importance of regular full skin checks. Enablers of screening awareness (statistical predictors): Young age, higher educational level and previous dermatological visits. Barriers to screening (statistical predictors): non‐Caucasian, male sex and lung transplant. Enablers of screening (statistical predictors): History of precancerous or cancerous skin lesion, single organ transplant (vs. multiorgan), urban residence, high income, care through high adhering centre, and more recent transplant years. Outcomes: Adherence associate with reduced keratinocyte carcinoma related morbidity/mortality. Characteristics and Key Findings of Included Clinician‐Focused Studies Author, yearCountryClinician typeStudy designOverall study aimNumber of participantsAdherence to screening dataFurther data relevant to review aims (barriers, enablers, other)Lam, 2019CanadaTransplant physicians and nursesCross‐sectional surveyEvaluate transplant clinicians' screening practices, policies and perceptions regarding skin cancer screening.18453% ensured at least annual screening for white patients; providers viewed as responsible: dermatology 70%, transplant physician 54%, nurses 42%, GP 40%. Perceived patient barriers (clinician‐reported): Long wait times, lack of availability of subspecialised transplant dermatologists, excessive distance to the nearest dermatologist, Insufficient priority (relative to other health issues) to obtain skin exam. Enablers of screening (statistically predicted): Having a screening policy, dermatologist within the centre. Awareness: Median importance rating of skin checks amongst clinicians: 10/10. Screening initiation (white patients): Only 15% pre‐transplant. Lloyd, 2015USATransplant physiciansCross‐sectional surveyInvestigate barriers amongst physicians to skin cancer screening in their patients.3719% had skin cancer screening in post‐transplant protocols. Barriers to screening: Perceived difficulty in accessing dermatologist; perceived overall lack of importance; perceived insufficient medical evidence to justify universal screening. Awareness: Only 16% aware of the American Academy of Dermatology (AAD) skin cancer screening recommendations for transplant patients. Screening initiation: Only 8% refer for screening pre‐transplant. Saleem, 2025GlobalHealth professional working in nephrologyCross‐sectional surveyAssess transplant clinicians screening practices in comparison to guidelines, and analyse factors associated with process.97Adherence: 84% recommended post‐transplant screening. Barriers to screening: Perceived financial constraints, perceived lack of patient awareness, perceived lack of patient awareness. Screening initiation: 69% recommended pre‐transplant screening. Perceived patient barriers (clinician‐reported): Long wait times, lack of availability of subspecialised transplant dermatologists, excessive distance to the nearest dermatologist, Insufficient priority (relative to other health issues) to obtain skin exam. Enablers of screening (statistically predicted): Having a screening policy, dermatologist within the centre. Awareness: Median importance rating of skin checks amongst clinicians: 10/10. Screening initiation (white patients): Only 15% pre‐transplant. Barriers to screening: Perceived difficulty in accessing dermatologist; perceived overall lack of importance; perceived insufficient medical evidence to justify universal screening. Awareness: Only 16% aware of the American Academy of Dermatology (AAD) skin cancer screening recommendations for transplant patients. Screening initiation: Only 8% refer for screening pre‐transplant. Barriers to screening: Perceived financial constraints, perceived lack of patient awareness, perceived lack of patient awareness. Screening initiation: 69% recommended pre‐transplant screening. Characteristics and Key Findings of Included System‐Focused Studies Author, yearCountrySettingStudy designOverall study aimNumber of centresAdherence to screening dataFurther data relevant to review aims (barriers, enablers, other)Cordaro, 2020UKSolid organ transplant centres (varied)Cross‐sectional surveyExplore skin cancer surveillance practices in UK transplant centres and barriers to surveillance.5155% offered post‐transplant screening, with various providers (e.g., dermatologist, referral to dermatology clinic, non‐dermatologists). 71% of these centres provide service at least annually. Barriers to screening (centre‐reported): Lack of funding to refer to dermatology, reliance on patient‐reported lesions. Screening initiation: 12% provided pre‐transplant screening by transplant physician or surgeon. Garg, 2009UK and AustraliaRenal Transplant CentresCross‐sectional surveyDetermine change in UK skin cancer surveillance practice since previous survey in 2000 and compare to practice in Australia.87 UK: 66% offered surveillance (FSE or inspection limited to exposed skin/patient reported lesions); 39% provided FSE; most performed by non‐dermatologists. Australia: 97% offered surveillance; 60% performed by dermatologist. 61% provided FSE. Enablers of screening: Structured protocol in Australian setting, more dermatologists per renal transplant recipient in Australia (author‐speculated).Piai, 2018ItalyPeripheral liver transplant centreSingle‐centre observational experienceCompare engagement with dermatologic work up pre and post implementation of regular dermatologist embedded in transplant centre.1Greater level of adherence with dermatologist post intervention. Barriers to screening: Lack of structured referral pathways, de‐centralised follow up at peripheral centres, limited integration of screening into standard post‐transplant protocol. Enablers of screening: Automatic referral system to dermatology, integration of screening into protocols, improved coordination between transplant specialists and dermatologist. Barriers to screening (centre‐reported): Lack of funding to refer to dermatology, reliance on patient‐reported lesions. Screening initiation: 12% provided pre‐transplant screening by transplant physician or surgeon. UK: 66% offered surveillance (FSE or inspection limited to exposed skin/patient reported lesions); 39% provided FSE; most performed by non‐dermatologists. Australia: 97% offered surveillance; 60% performed by dermatologist. 61% provided FSE. Barriers to screening: Lack of structured referral pathways, de‐centralised follow up at peripheral centres, limited integration of screening into standard post‐transplant protocol. Enablers of screening: Automatic referral system to dermatology, integration of screening into protocols, improved coordination between transplant specialists and dermatologist. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study.